Acadia wins patent litigation for NUPLAZID; court rules for Acadia on infringement and validity

ACADIA PHARMACEUTICALS INC

U.S. District Court for Delaware ruled in Acadia's favor in Pimavanserin II Cases regarding '721 formulation patent for NUPLAZID.
Court ruled for Acadia on both infringement and validity arguments against Aurobindo Pharma and MSN Laboratories.
Acadia entered a 12-year lease for ~52,771 sq ft Princeton executive office; 210 Lease starts by Jan 2026 with $1.9M first-year rent.
Amended current 502 Lease to terminate 5 days after 210 Lease commencement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.